Contact The Gross Law Firm by October 6, 2025 Deadline to Join Class Action Against Altimmune, Inc.(ALT)

Core Viewpoint - Altimmune, Inc. faced significant stock price decline following the announcement of disappointing results from its IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint analysis [1][2]. Group 1: Company Performance - The IMPACT Phase 2b MASH trial results were released on June 26, 2025, revealing that while there was a positive trend in fibrosis improvement, the results did not meet statistical significance due to a higher-than-expected placebo response [1]. - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a dramatic decline of 53.2% in just one day [1]. Group 2: Legal Actions - Shareholders who purchased shares of Altimmune during the class period from August 10, 2023, to June 25, 2025, are encouraged to contact the Gross Law Firm regarding potential lead plaintiff appointments in a class action lawsuit [1][2]. - The deadline for shareholders to register for the class action and seek lead plaintiff status is October 6, 2025 [2]. Group 3: Firm's Commitment - The Gross Law Firm is dedicated to protecting the rights of investors affected by deceitful practices and aims to ensure companies adhere to responsible business practices [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that led to artificial inflation of stock prices [3].